Workflow
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Businesswire· 2025-11-05 12:01
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2025. "The Viridian team continues to deliver strong results, highlighted by the successful submission of our BLA for veligrotug, completing enrollment in both pivotal c. ...
The Labor Economy Becomes the Innovation Economy
PYMNTS.com· 2025-11-05 12:00
My hometown of Baltimore was the first city to install gas street lights in 1816 in an effort to curb crime. More cities quickly followed suit.  By the turn of the century, every evening at dusk, lamplighters walked the streets with their ladders and torches, igniting gas lamps one by one. Twenty years later, electric streetlights became more commonplace, and lamplighters became more or less an extinct species.By completing this form, you agree to receive marketing communications from PYMNTS and to the shar ...
Precision Concepts expands packaging portfolio with Comar purchase
Yahoo Finance· 2025-11-05 12:00
Core Insights - Precision Concepts International (PCI) has acquired Comar, creating a larger rigid packaging platform to serve consumer and healthcare sectors [1][4] - The financial details of the acquisition were not disclosed, but it is part of The Sterling Group's strategy to enhance its portfolio [1][2] - The combined entity will benefit from increased geographic, customer, and end market diversification, positioning itself as a leader in specialty packaging [4] Company Overview - PCI, based in Huntersville, North Carolina, specializes in rigid packaging and serves small to mid-sized brands across personal care, household, and food and beverage categories [2][3] - Comar, established in 1949, produces rigid packaging and plastic medical components, operating nine sites in the US, along with locations in Puerto Rico and Ireland [1][4] - PCI operates nine manufacturing plants across Canada, the US, and Costa Rica, employing approximately 1,200 people [3] Strategic Implications - The acquisition is expected to enhance PCI's capabilities in providing industry-leading rigid packaging solutions and exceptional service [3] - PCI's CEO emphasized that the merger will allow for a broader range of products and services, delivering more value to customers [3] - The Sterling Group has a history of backing 76 platform buyouts and multiple add-on transactions, with a total deal value exceeding $25 billion [2]
In a volatile week for interest rates, mortgage demand pulled back
CNBC· 2025-11-05 12:00
Last week saw a big swing in mortgage interest rates, and that took a toll on demand. Total mortgage application volume fell 1.9% compared with the previous week, according to the Mortgage Bankers Association's seasonally adjusted index.For the week, the average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances, $806,500 or less, increased to 6.31% from 6.30% for loans with a 20% down payment. That was the weekly average, but rates actually fell to the lowest level in ove ...
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
Globenewswire· 2025-11-05 12:00
BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its Premarket Approval application (PMA) for Hyalofast—its resorbable, hyaluronic acid-based scaffold used with autologous bone marrow aspirate concentrate (BMAC) for treating articular cartilage defects in the knee. The Company also reported results from its U.S. pivotal Phase III FastTRACK clinical ...
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
Globenewswire· 2025-11-05 12:00
ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026ORX142: Phase 1 data support highly differentiated profile; Expect to initiate patient studies in Q1 2026 ORX489: Advancing in IND-en ...
Microbix Addresses Cybersecurity Incident
Globenewswire· 2025-11-05 12:00
MISSISSAUGA, Ontario, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is addressing a cybersecurity incident relating to a ransomware attack that has had no impact on operations but involved the theft of data. Microbix is actively addressing the incident, which highlights the importance of the Company’s ongoing program to strengthen its cybersecurity. An international hacker group, respon ...
OPENLANE, Inc. Reports Third Quarter 2025 Financial Results
Prnewswire· 2025-11-05 12:00
Accessibility StatementSkip Navigation CARMEL, Ind., Nov. 5, 2025 /PRNewswire/ -- OPENLANE, Inc. (NYSE: KAR), today reported its third quarter financial results for the period ended September 30, 2025. "OPENLANE's strategy — and the investments we've made to accelerate it — produced another strong quarter of organic growth and profitability, including 8% consolidated revenue growth and $87 million in Adjusted EBITDA," said Peter Kelly, CEO of OPENLANE. "We grew dealer-to-dealer volumes by 14%, significantly ...
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
Prnewswire· 2025-11-05 12:00
KSI-101 is novel, potent and high strength (100 mg/mL) antibody-based investigational therapy with a bispecific mechanism of action targeting both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). Week 20 Data Highlights from Phase 1b APEX Study in Patients with Macular Edema Secondary to Inflammation – Baseline to Week 20 (Patients dosed at Weeks 0, 4, 8 and 12) Dose Level Accessibility StatementSkip Navigation PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: ...
Aurora Cannabis Announces Fiscal 2026 Second Quarter Results
Prnewswire· 2025-11-05 12:00
Accessibility StatementSkip Navigation NASDAQ | TSX: ACB EDMONTON, AB, Nov. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025. "Aurora's quarterly performance highlights our continued focus on profitable growth. We achieved record net revenue for global medical cannabis representing a 15% ye ...